Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors

Journal of Neuro-Oncology

Volumn 64, Issue 1, 2003, Pages 139-146

  Glick, Roberta P ^a,b,c   Lichtor, Terry ^a,b   Panchal, Ripul ^a   Mahendra, Anjuli ^a   Cohen, Edward P ^c  

^a Jr Hospital of Cook County   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cytokine; Gene therapy; Interleukin 2; Tumor vaccine

Indexed keywords

INTERLEUKIN 12; RETROVIRUS VECTOR; TUMOR CELL VACCINE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN TUMOR; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER SURVIVAL; CELL DEATH; CELL SECRETION; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENT; FEMALE; FIBROBLAST; GLIOMA; GLIOMA CELL; MOUSE; NONHUMAN; TUMOR IMMUNITY;

EID: 0043065277     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024923001963     Document Type: Conference Paper

References (32)

1. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Lienard D, Cerundolo V, Cerottini JC, Romero P: Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164: 1125-1131, 2000
2. Gabrilove JL, Jakubowski A: Hematopoietic growth factors: Biology and clinical application. J Natl Cancer Inst 10: 73-77, 1990
3. Kelso A: Cytokines: Structure function and synthesis. Curr Opin Immunol 2(2): 215-225, 1989
4. Borden EC, Sondel PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65(3 suppl): 800-814, 1990
5. Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer. Ann Intern Med 108: 853-864, 1988
6. Lotze MT, Chang AE, Seipp CA et al.: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity and histologic findings. JAMA 256: 3117-3124, 1986
7. Pizza G, Viza D, DeVince C, Vichi-Pascuuchi JM, Busutti L, Bergami T: Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: A pilot study. Cytokine Res 7: 45-48, 1988
8. Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R: A pilot study of intralymphatic interleukin-2. II Clinical and biological effects. J Biol Response Modif 9: 81-86, 1990
9. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, DeVinci C, Bacchini P, Morelli MC, Corrado G: Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepato-Gastroenterology 36: 352-356, 1989
10. Bubenik J, Viotenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, Simova F, Jandlova T: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 19: 279-282, 1988
11. Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from urine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54(10): 2531-2535, 1994
12. Kim TS, Russell SJ, Collins MK, Cohen EP: Immunity to B 16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51(2): 283-289, 1992
13. Tahara H, Zeh HJ 3rd, Storkus WJ et al.: Fibroblasts genetically engineered to secrete interleukin 12 can supress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54(1): 182-189, 1994
14. Fakhrai H, Shawler DL, Gjerset R et al.: Cytokine gene therapy with interleukin-2 transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591-601, 1995
15. Sobol RE, Fakhrai H, Shawler DL et al.: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2: 164-167, 1995
16. Lichtor T, Glick PP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83: 1038-1044, 1995
17. Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen EP: Immunogene therapy with interleukin-2-screting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg 94: 287-292, 2001
18. Glick RP, Lichtor T, De Zoeten E, Deshmukh P, Cohen EP: Prolongation of survival of mice with glioma treated with semiallogeneic firoblasts secreting interleukin-2. Neurosurgery 45: 867-874, 1999
19. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8: 1065-1072, 1997
20. Sampson J, Archer G, Ashley D, Fuchs H, Hale L, Dranoff G, Bigner D: Subcutaneous vaccination with irradiated cytokine producing tumor cells stimulates CD8+ cell mediated immunity against tumors located in the 'immunogically privileged' CNS. Porc Natl Acad Sci USA 93: 10399-10404, 1996
21. Giezeman-Smits K, Okada H, Brissette-Storkus C, Villa L, Attanucci J, Lotze M, Pollack I, Bozik M, Chambers W: Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60: 2449-2457, 2000
22. Herrlinger U, Kramm C, Johnston K, Louis D, Finkelstein D, Reznikoff G, Dranoff Gbreakefield X, Yu J: Vaccination for experimental gliomas using GM-CSF transduced glioma. Cancer Gene Ther 4: 345-352, 1997
23. Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon beta gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626-1633, 1999
24. Yamada G, Kitamura Y, Sonoda H, Harda H, Taki S, Mulligan RC, Osawa H, Diamantstein T, Yokoyama S, Taniguchi T: Retroviral expression of the human IL-2 gene in a murine T cell line results in a cell growth autonomy and tumorigenicity. EMBO J 6: 2706-2709, 1987
25. Cobere-Garapin F, Horodniceanu F, Kourilsky P, Garapin A: A new dominant hybrid selective marker for eucaryotic cells. J Mol Biol 150: 1-14, 1981
26. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406, 1988
27. Griffitt W, Glick RP, Lichtor T, Haughton DE, Cohen EP: Development of a new mouse brain tumor model using implantable micro-cannulas. J Neuro-Oncol 41: 17-120, 1999
28. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2 secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9: 464-469, 2002
29. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182, 1997
30. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH: Bone marrow-derived dendritic cells pulsed with tumor homogenate induced immunity against syngeneic intracerebral glioma. J Neuroimmunol 103: 16-25, 2000
31. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22: 613-621, 2002
32. Hui KM, Sim TF, Foo TT, Oei A-A: Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143: 3835-3843, 1989